<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trihexyphenidyl: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trihexyphenidyl: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trihexyphenidyl: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="10022" href="/d/html/10022.html" rel="external">see "Trihexyphenidyl: Drug information"</a> and <a class="drug drug_patient" data-topicid="11124" href="/d/html/11124.html" rel="external">see "Trihexyphenidyl: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1062725"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-Parkinson's Agent</span>;</li>
<li>
<span class="list-set-name">Anticholinergic Agent</span>;</li>
<li>
<span class="list-set-name">Antidote, Drug-induced Dystonic Reactions</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812558"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b045cfb0-6f2b-4f4e-a064-35e970c73c7e">Dystonia in cerebral palsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dystonia in cerebral palsy: </b>Limited data available: Children and Adolescents: Oral: Initial: 0.1 to 0.2 mg/kg<b>/day </b>in 2 to 3 divided doses; after the first week, titrate weekly or every 2 weeks as tolerated (eg, increase by 0.15 mg/kg/day or increase by 10% to 20%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21498790','lexi-content-ref-21310336','lexi-content-ref-19182155','lexi-content-ref-17690057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21498790','lexi-content-ref-21310336','lexi-content-ref-19182155','lexi-content-ref-17690057'])">Ref</a></span>). Usual maximum daily dose: 0.75 mg/kg/<b>day</b> in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17690057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17690057'])">Ref</a></span>). Doses as high as 2.6 mg/kg/day in 3 divided doses have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19182155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19182155'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729856"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F52729857"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F231193"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10022" href="/d/html/10022.html" rel="external">see "Trihexyphenidyl: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="265846fb-48a4-4d1d-b1b0-951c91e73477">Extrapyramidal symptoms, medication-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extrapyramidal symptoms (eg, dystonia and parkinsonism), medication-induced (treatment):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Anticholinergic agents are not recommended for the treatment of akathisia or tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-2904118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-2904118'])">Ref</a></span>). Duration of therapy is based on the severity of EPS reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects), and patient risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9359953','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9359953','lexi-content-ref-19955388'])">Ref</a></span>). Some experts recommend attempting taper and discontinuation after several weeks to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22651987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22651987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 mg/day; increase as necessary to usual range: 5 to 15 mg/day in 3 to 4 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f01595c-b615-45af-983e-0a196d0c3f4f">Parkinsonism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinsonism:</b>
<b>Oral:</b> Initial: 1 mg/day, increase by 2 mg increments at intervals of 3 to 5 days; usual dose: 6 to 10 mg/day in 3 to 4 divided doses; doses of 12 to 15 mg/day may be required. Consider dosage reduction when used concomitantly with levodopa, the usual dose of each may need to be reduced. Usual range: 3 to 6 mg/day in divided doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome, exacerbation of parkinsonism, and withdrawal symptoms (eg, palpitations, headache, insomnia, fainting, and nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3984771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3984771'])">Ref</a></span>)). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6109453','lexi-content-ref-6116743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6109453','lexi-content-ref-6116743'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991455"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988768"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F231163"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (30% to 50%), xerostomia (30% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (30% to 50%), nervousness (30% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (30% to 50%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Paradoxical bradycardia (sinus bradycardia) (Blumensohn 1986), tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (Zhao 2022), hypohidrosis (Zhao 2022), skin rash, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: SIADH (Zhao 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (Zhao 2022), paralytic ileus, toxic megacolon, vomiting (Zhao 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary hesitancy, urinary retention (Zhao 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Zhao 2022), asthenia, choreiform movements (Warne 1979, cognitive dysfunction (including confusion and memory impairment) (Zhao 2022), delusion, drowsiness, euphoria (Jellinek 1977), hallucination (Zhao 2022), headache, myasthenia gravis (Ueno 1987), neuroleptic malignant syndrome (with abrupt withdrawal), paranoid ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (including tardive dyskinesia [orobuccal] (Hauser 1993, Zhao 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma (including blindness), cycloplegia, increased intraocular pressure, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: High fever (Zhao 2022), malignant hyperthermia (Zhao 2022)</p></div>
<div class="block coi drugH1Div" id="F231176"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to trihexyphenidyl or any component of the formulation; narrow angle glaucoma.</p></div>
<div class="block war drugH1Div" id="F231160"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anhidrosis/hyperthermia: May cause anhidrosis and hyperthermia. Severe anhidrosis and fatal hyperthermia have occurred; use with caution in hot weather or during exercise, especially when administered concomitantly with other anticholinergic drugs to chronically ill patients, patients with alcohol use disorder, patients with CNS disease, or persons doing manual labor in a hot environment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); monitor patients requiring long-term use.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May precipitate angle closure with an increase in intraocular pressure. If blurring of vision occurs, consider the possibility of narrow angle glaucoma; blindness because of aggravation of narrow angle glaucoma has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI obstruction: Use with caution in patients with obstructive disease of the GI tract.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; blindness after long-term use due to narrow angle glaucoma has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: May impair memory and further exacerbate cognitive deficits in elderly patients; in high doses may cause confusion, delirium, and hallucinations (Holloman 1997; Tonda 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tardive dyskinesia: Not recommended for use in patients with tardive dyskinesia unless concomitant Parkinson disease or tardive dystonia exists (Kang 1986); trihexyphenidyl does not relieve symptoms of tardive dyskinesia and may potentially exacerbate symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome (NMS), exacerbation of Parkinsonism, and withdrawal symptoms including tension, irritability, perspiration, palpitations, headache, insomnia, abdominal distress, anorexia, faint or choking feelings, nausea, and photophobia (McInnis 1985). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (Manos 1981a; Manos 1981b).</p></div>
<div class="block foc drugH1Div" id="F231170"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F231156"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F231179"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Trihexyphenidyl HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/mL (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trihexyphenidyl HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.18 - $0.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.36 - $1.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868509"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg</p></div>
<div class="block admp drugH1Div" id="F52613973"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken before or after meals (if excessive dry mouth develops, consider administering before meals unless it causes nausea); tolerated best if administered in 3 daily doses and with food. High doses (&gt;10 mg/day) may be divided into 4 doses, at meal times and at bedtime.</p></div>
<div class="block adm drugH1Div" id="F803231"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered before or after meals (if excessive dry mouth develops, consider administering before meals unless it causes nausea; postencephalitic patients who are prone to excessive salivation may prefer to take after meals); tolerated best if given in 3 daily doses and with food. High doses (&gt;10 mg/day) may be divided into 4 doses (at each meal and at bedtime).</p></div>
<div class="block sts drugH1Div" id="F10288169"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53569339"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunctive treatment of Parkinson's disease and treatment of drug-induced extrapyramidal symptoms (EPS) (FDA approved in adults); has also been used for treatment of dystonia in cerebral palsy</p></div>
<div class="block mst drugH1Div" id="F231237"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Trihexyphenidyl may be confused with trifluoperazine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Trihexyphenidyl is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its highly anticholinergic properties. It is not recommended for the prevention or treatment of extrapyramidal symptoms with antipsychotics. In the treatment of Parkinson disease, more effective agents are available (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300176"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F231165"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: Trihexyphenidyl may enhance the adverse/toxic effect of Lisuride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F9626964"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken before or after meals; tolerated best if given with food.</p></div>
<div class="block pri drugH1Div" id="F13823805"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. One case report did not show evidence of adverse events after trihexyphenidyl administration during pregnancy (Robottom 2011).</p></div>
<div class="block mopp drugH1Div" id="F53569338"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure monitoring and gonioscopic evaluations (baseline and at regular intervals), anticholinergic adverse reactions (patients on long-term therapy)</p></div>
<div class="block pha drugH1Div" id="F231159"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exerts a direct inhibitory effect on the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly on the muscle itself and indirectly through parasympathetic nervous system (inhibitory effect)</p></div>
<div class="block phk drugH1Div" id="F231175"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hydroxylation of the alicyclic groups (Brocks 1999)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 33 hours (Brocks 1999)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1.3 hours (Brocks 1999) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and bile (Brocks 1999)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F231181"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-trihex | Artane | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexifenidilo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Delpark | Heximax | Hexinor | Hexiphen | Parkifen | Parkitrol | Perkinor | Tridyl | Trihexy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Parcisol | Parkisan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Artane | Triexidyl</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Artane | Tenvatil | Tonaril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An tan | Artane | Benzhexol | Benzhexol hydrochloride | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexifenidilo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Artane | Parkopan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Artane | Tremol | Tremolin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cyclodol | Parkopan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Parkinol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexyphenidyl richard</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Agitane | Artane | Bentex | Benzhexol | Benzhexol dc | Broflex | Broflex bms | Trihexyphenidy | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Artane | Benzhexol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Adtendyl | Apo-trihex | Artandyl | Artane | Benzhexol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Arkicel | Arkine | Artane | Hexymer | Parkinal | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Artane | Broflex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Artane | Partane | Rodenal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Antichol | Barohexy | Benz | Bexol | Dyskinil | Dystonil | Ecitane | Emelaxy | Epsinil | Hex | Hexylent | Lahexy | Manohexy | Maphyl | Matcalm | Pacitane | Parkin | Parkinta | Parkitane | Parnil | Parnon | Relihexy | Tanzee | Thp | Tri ex | Triden | Trihexy | Trikotame | Triphen | Trit 2 | Tryal | Xydyl</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Samhexol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Artane | Parkizole</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Artane | Parkines towa | Parkiness merck hoei | Parkisonal | Pyramistin | Sedrena | Stobrun | Topcron | Tremin | Trihexin | Trihexyphenidyl Hcl Nipro | Triphedinon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Benzhexol | Parkin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexin | Trihexyne | Trihexyphenidyl hydrochlorid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Artane | Benzhexol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cyclodol | Parkisan | Parkopan | Triphen | Triphenidyl</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Artane | Cyclodol | Parkisan | Parkopan | Triphenidyl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Artane | Hipokinon | Trihexifenidilo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aca | Apo-trihex | B-Hex | Benzhexol | Pharmaniaga benzhexol | Uphazhexol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Axzol | Babazole | Benzhexol | Cinnamon benzhexol | Embazol | Oxazol | Pbenz | Royale benzhexol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Hexidyl | Pacitane</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Artane | Parkopan | Triphenidyl</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Artane | Trihexyphenidyl</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Desagit</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cyclodol | Parkopan | Romparkin | Trihexyphenidyl | Trihexyphenidyl ferein | Trihexyphenidyl organica | Trihexyphenidyl ph | Trihexyphenidyl pharmstandart | Triphen</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Artane | Pargitan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-trihex | Artyl | B-Hex | Beahexol | Benzhexol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aca | Acamed | Artane | Benzhexol | Pozhexol | Tridyl</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apo-trihex | Artane | Parkizol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Artane | Artine | Atan | B.h.l | Benzhexol | Benzox | Parkindyl | Partane | Switane</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cyclodol | Parcopan | Parkopan | Trifen</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Benzhexol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Artane</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Artane | Benzhexol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Benzhexol</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo-trihex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21498790">
<a name="21498790"></a>Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. <i>J Child Neurol</i>. 2011;26(7):810-816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/21498790/pubmed" id="21498790" target="_blank">21498790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3769769">
<a name="3769769"></a>Blumensohn R, Razoni G, Shalev A, Munitz H. Bradycardia due to trihexyphenidyl hydrochloride. <i>Drug Intell Clin Pharm</i>. 1986;20(10):786-787. doi:10.1177/106002808602001012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/3769769/pubmed" id="3769769" target="_blank">3769769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10952768">
<a name="10952768"></a>Brocks DR, “Anticholinergic Drugs Used in Parkinson's Disease: An Overlooked Class of Drugs From a Pharmacokinetic Perspective,” <i>J Pharm Pharmaceut Sci</i>, 1999, 2(2):39-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/10952768/pubmed" id="10952768" target="_blank">10952768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21310336">
<a name="21310336"></a>Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. <i>Pediatr Neurol</i>. 2011;44(3):202-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/21310336/pubmed" id="21310336" target="_blank">21310336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22651987">
<a name="22651987"></a>Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? <i>J Psychopharmacol.</i> 2012;26(9):1167-1174. doi:10.1177/0269881112447988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/22651987/pubmed" id="22651987" target="_blank">22651987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8232363">
<a name="8232363"></a>Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. <i>Mov Disord</i>. 1993;8(4):512-514. doi:10.1002/mds.870080417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/8232363/pubmed" id="8232363" target="_blank">8232363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359953">
<a name="9359953"></a>Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. <i>Am J Health Syst Pharm</i>. 1997:54(1):2461-2477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/9359953/pubmed" id="9359953" target="_blank">9359953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-852367">
<a name="852367"></a>Jellinek T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. <i>Dis Nerv Syst</i>. 1977;38(5):353-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/852367/pubmed" id="852367" target="_blank">852367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2904118">
<a name="2904118"></a>Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. <i>Mov Disord</i>. 1986;1(3):193-208. doi: 10.1002/mds.870010305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/2904118/pubmed" id="2904118" target="_blank">2904118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955388">
<a name="19955388"></a>Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. <i>Schizophr Bull</i>. 2010;36(1):94-103. doi: 10.1093/schbul/sbp130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/19955388/pubmed" id="19955388" target="_blank">19955388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6109453">
<a name="6109453"></a>Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. <i>Am J Psychiatry</i>. 1981a;138(2):184-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/6109453/pubmed" id="6109453" target="_blank">6109453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6116743">
<a name="6116743"></a>Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt? <i>J Nerv Ment Dis</i>. 1981b;169(10):659-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/6116743/pubmed" id="6116743" target="_blank">6116743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3984771">
<a name="3984771"></a>McInnis M, Petursson H. Withdrawal of trihexyphenidyl. <i>Acta Psychiatr Scand</i>. 1985;71(3):297-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/3984771/pubmed" id="3984771" target="_blank">3984771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19182155">
<a name="19182155"></a>Rice J and Waugh MC, "Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy," <i>Child Neurol</i>, 2009, 24(2):176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/19182155/pubmed" id="19182155" target="_blank">19182155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22045287">
<a name="22045287"></a>Robottom BJ and Reich SG, "Exposure to High Dosage Trihexyphenidyl During Pregnancy for Treatment of Generalized Dystonia: Case Report and Literature Review," <i>Neurologist</i>, 2011, 17(6):340-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/22045287/pubmed" id="22045287" target="_blank">22045287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17690057">
<a name="17690057"></a>Sanger TD, Bastian A, Brunstrom J, et al, "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy," <i>J Child Neurol</i>, 2007, 22(5):530-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/17690057/pubmed" id="17690057" target="_blank">17690057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PackPharm.1">
<a name="PackPharm.1"></a>Trihexyphenidyl hydrochloride tablets [prescribing information]. Buffalo Grove, IL: Pack Pharmaceuticals; June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.1">
<a name="Pai.1"></a>Trihexyphenidyl hydrochloride oral solution [prescribing information]. Greenville, SC: Pai Pharmaceutical Associates; October 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7997388">
<a name="7997388"></a>Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. <i>Pharmacotherapy</i>. 1994;14(5):543-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/7997388/pubmed" id="7997388" target="_blank">7997388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3033545">
<a name="3033545"></a>Ueno S, Takahashi M, Kajiyama K, et al. Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. <i>Neurology</i>. 1987;37(5):832-833. doi:10.1212/wnl.37.5.832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/3033545/pubmed" id="3033545" target="_blank">3033545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-470689">
<a name="470689"></a>Warne RW, Gubbay SS. Choreiform movements induced by anticholinergic therapy. <i>Med J Aust</i>. 1979;1(10):465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/470689/pubmed" id="470689" target="_blank">470689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443324">
<a name="32443324"></a>Zhao J, Xu G, Feng C, et al. Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: a case report. <i>Medicine (Baltimore)</i>. 2020;99(20):e20129. doi:10.1097/MD.0000000000020129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trihexyphenidyl-pediatric-drug-information/abstract-text/32443324/pubmed" id="32443324" target="_blank">32443324</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12863 Version 255.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
